The Boston Lung Cancer Survival Cohort

波士顿肺癌生存队列

基本信息

批准号：
10603494
负责人：
David C Christiani
金额：
$ 123.12万
依托单位：
HARVARD SCHOOL OF PUBLIC HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-06-01 至 2028-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10603494
关键词：
Address Adult Air Pollution Alternative Therapies Archives Award Biological Biological Markers Boston Cancer Center Cancer Patient Cancer Survivor Cancer Survivorship Cessation of life Chest imaging Clinical Collaborations Collection Creativeness DNA Dana-Farber Cancer Institute Data Data Management Resources Databases Diagnosis Diagnostic Dimensions Disease Progression Education Electronic Health Record Enrollment Environment Environmental Exposure Epidemiologic Methods Epidemiology Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Epigenetic Process Erlotinib Evaluation Funding Gefitinib General Hospitals Genetic Genomics Grant Health Health Insurance Heterogeneity High Resolution Computed Tomography Image Immune checkpoint inhibitor Immunotherapy Income Individual Infrastructure Interdisciplinary Study International Investigation Laboratories Leukocytes Libraries Longterm Follow-up Lung Lung Adenocarcinoma Malignant Neoplasms Malignant neoplasm of lung Massachusetts Measures Medical Informatics Meteorology Methodology Modeling Molecular Monitor Mutation Natural History Neighborhoods Newly Diagnosed Non-Small-Cell Lung Carcinoma Nucleic Acids Occupational Oncogenic Output Paper Participant Pathology Patients Peripheral Phenotype Plasma Positron-Emission Tomography Productivity Prognostic Marker Publishing Pulmonary function tests Quality of life Questionnaires RNA ROS1 gene Race Recording of previous events Research Research Personnel Resource Sharing Resources Risk Factors Sampling Serum Smoking Socioeconomic Status Source Specimen Survivors Therapeutic Tissue Banks Tissue Microarray Tissue Survival Tissues Translational Research Treatment outcome Treatment-related toxicity Tumor Tissue U-Series Cooperative Agreements Update Urine Work X-Ray Computed Tomography anticancer research automated image analysis biobank bioinformatics infrastructure built environment cancer diagnosis cancer epidemiology cancer heterogeneity cancer survival cancer therapy clinical investigation cohort comorbidity data management data repository dietary driver mutation economic determinant effective therapy empowerment epidemiologic discoveries follow-up genetic epidemiology genotyped patients improved income insurance indexing innovation lung cancer screening method development minority patient mortality multidisciplinary mutational status new technology novel novel therapeutic intervention novel therapeutics phenome phenomics predictive marker prognostic programs pulmonary function racial disparity radiomics recruit repository response segregation social determinants socioeconomics survival outcome targeted treatment traditional therapy translational medicine treatment disparity treatment response treatment strategy tumor vaping

项目摘要

The Boston Lung Cancer Survival (BLCS) cohort is a Cancer Epidemiology Cohort of more than 12,000 lung cancer cases enrolled at Massachusetts General Hospital and the Dana-Farber Cancer Institute since 1992. This rich resource enables research to understand lung cancer heterogeneity that has already identified valuable prognostic markers and stimulated new treatment strategies. For example, the BLCS supported the first discovery of the association between EGFR mutations and response to therapy with EGFR-tyrosine kinase inhibitors and enabled research on effective treatments for non-small cell lung cancer patients with ALK and ROS1 rearrangements. In 2017, the cohort evolved into a survivor epidemiology cohort that is sustained by a U01 grant until May 2023. Our progress during the first U01 funding cycle (2017–2022) is substantial—we have published over 100 papers, supported 6 new grants, and worked with 50 collaborators nationally and internationally. With the U01 award expiring soon, there is an urgency to renew to: 1) maintain this first and most comprehensive lung cancer survivor cohort with the longest follow-up period—an unmatched source of data for translational research; 2) establish an innovative, detailed phenotyping database via automated image analysis of high-resolution computed tomography, as well as a radiomics database; 3) enable the established infrastructure to facilitate internal and external investigators to pilot methodologic approaches that will turn into productive multidisciplinary project grants by focusing on survival and treatment toxicity; and 4) leverage the Dana-Farber/Harvard Cancer Center Lung Program resources for creative multidisciplinary collaborations focused on treatment outcomes. Renewed funding is also critical to recruit 2,500 new cases (for a total of 14,500 cases) to this already large cohort. New cases are vitally important to: 1) facilitate comparison of new treatments and traditional therapy as well as evaluation of new clinical investigation in an ever-changing therapeutic environment; 2) allow us to collect more cases with driver mutation data, as well as those treated with immune checkpoint inhibitors; 3) promote collection of repeated biological samples to support developing prognostic/predictive biomarkers; 4) allow us to collect detailed data enabling assessment of environmental determinants as well as racial and socioeconomic determinants of survival; and 5) empower our studies to identify radiomic, genomic, epigenetic, and other phenomic biomarkers, environmental determinants, and racial and socioeconomic determinants that are relevant to patient survival to guide improved lung cancer screening and treatment strategies. The BLCS is one of the largest lung cancer survival cohorts and encompasses a wealth of biomarker, tumor molecular characterization, imaging, lung function, genetic, epigenetic, traditional epidemiologic risk factor, and electronic health record data. With continued support, this comprehensive cohort will provide unique opportunities to explore predictors of lung cancer survival and treatment outcomes, catalyzing powerful translational research that improves the health of individuals with lung cancer.

波士顿肺癌生存 (BLCS) 队列是一个包含 12,000 多个肺部的癌症流行病学队列自 1992 年以来，麻省总医院和丹娜法伯癌症研究所登记的癌症病例。这种丰富的资源使研究能够了解已经确定的肺癌异质性有价值的预后标志物并激发了新的治疗策略，例如，BLCS 支持首次发现 EGFR 突变与 EGFR 酪氨酸激酶治疗反应之间的关联抑制剂，并促进了对患有 ALK 和 ALK 的非小细胞肺癌患者的有效治疗研究 2017 年，ROS1 重新排列，该队列演变为幸存者流行病学队列，并由 U01 拨款截止至 2023 年 5 月。我们在第一个 U01 资助周期（2017-2022）期间取得的进展是巨大的——我们发表了 100 多篇论文，支持了 6 项新资助，并与全国 50 名合作者合作随着 U01 奖项即将到期，迫切需要续签：1) 维持这一奖项并最全面、最长随访期的肺癌幸存者队列——无与伦比的来源转化研究数据；2）通过自动化图像建立创新、详细的表型数据库高分辨率计算机断层扫描以及放射组学数据库的分析；3) 促进内部和外部调查人员试点方法学方法的基础设施，这些方法学方法将变成通过关注生存和治疗毒性来提供富有成效的多学科项目资助；以及 4) 利用丹娜—法伯癌症研究所/哈佛大学癌症中心肺项目资源用于创造性的多学科合作重点关注治疗结果。更新的资金对于招募 2,500 个新病例（总计）也至关重要。 14,500 例）对于这个已经很大的队列来说至关重要：1）促进新病例的比较。疗法和传统疗法以及在不断变化的情况下对新临床研究的评估治疗环境；2）允许我们收集更多具有驱动突变数据的病例以及接受治疗的病例使用免疫检查点抑制剂；3）促进重复生物样本的收集以支持开发预后/预测生物标志物；4) 让我们能够收集详细的数据，以便评估环境生存的决定因素以及种族和社会经济决定因素；5）使我们的研究能够识别放射组学、基因组学、表观遗传学和其他表型生物标志物、环境决定因素和种族与患者生存相关的社会经济决定因素，以指导改进肺癌筛查 BLCS 是最大的肺癌生存队列之一，涵盖丰富的生物标志物、肿瘤分子表征、成像、肺功能、遗传、表观遗传、传统在持续的支持下，这个全面的队列研究了流行病学危险因素和电子健康记录数据。将为探索肺癌生存和治疗结果的预测因素提供独特的机会，促进强有力的转化研究，改善肺癌患者的健康。

项目成果

期刊论文数量（48）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Quantile regression for survival data in modern cancer research: expanding statistical tools for precision medicine.

现代癌症研究中生存数据的分位数回归：扩展精准医学的统计工具。

DOI：
发表时间：
2019-06
期刊：
影响因子：
5.3
作者：
Hong, Hyokyoung G;Christiani, David C;Li, Yi
通讯作者：
Li, Yi

Epigenomic analysis of 5-hydroxymethylcytosine (5hmC) reveals novel DNA methylation markers for lung cancers.

5-羟甲基胞嘧啶 (5hmC) 的表观基因组分析揭示了肺癌的新型 DNA 甲基化标记。

DOI：
发表时间：
2020
期刊：
影响因子：
0
作者：
Wang, Zhihui;Du, Mulong;Yuan, Qianyu;Guo, Yichen;Hutchinson, John N;Su, Li;Zheng, Yinan;Wang, Jun;Mucci, Lorelei A;Lin, Xihong;Hou, Lifang;Christiani, David C
通讯作者：
Christiani, David C

Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.

PD-(L)1 阻断单一疗法与 PD-(L)1 阻断加化疗在一线 PD-L1 阳性晚期肺腺癌中的疗效比较：一项队列研究。

DOI：
发表时间：
2023-07
期刊：
影响因子：
0
作者：
Elkrief, Arielle;Alessi, Joao M Victor;Ricciuti, Biagio;Brown, Samantha;Rizvi, Hira;Preeshagul, Isabel R;Wang, Xinan;Pecci, Federica;Di Federico, Alessandro;Lamberti, Giuseppe;Egger, Jacklynn V;Chaft, Jamie E;Rudin, Charles M;Riely, Gregory J
通讯作者：
Riely, Gregory J

D R A F T Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer

D R A F T 综合放射基因组学模型预测高级别浆液性卵巢癌新辅助化疗的反应

DOI：
发表时间：
2024-09-14
期刊：
影响因子：
0
作者：
M. Crispín;R. Woitek;E. Moore;M. Reinius;L. Beer;V. Bura;L. Rundo;C. McCague;Stephan Ursprung;L. E. Sanchez;P. Martin;F. Mouliere;D. Ch;ran;a;ran;a;J. Morris;T. Goranova;A. Piskorz;N. Singh;A. Sahdev;R. Pintican;Marta Zerunian;H. Addley;M. Jimenez;F. Markowetz;E. Sala;J. Brenton
通讯作者：
J. Brenton

Feature selection of ultrahigh-dimensional covariates with survival outcomes: a selective review.

超高维协变量与生存结果的特征选择：选择性审查。